Evaluating nano-based medications for treating Enterococcus faecalis infections in root canals
Antimicrobial Efficacy of Nano-Based Intracanal Medications on Enterococcus Faecalis
This study tests whether new nano-based medications can help reduce harmful bacteria in root canals for people with persistent infections after dental treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 19 Years to 60 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT06533215 on ClinicalTrials.gov |
What this trial studies
This study investigates the antimicrobial effects of nano-based intracanal medications, specifically triple antibiotic-loaded chitosan nanoparticles and chlorhexidine loaded with silver nanoparticles, on reducing Enterococcus faecalis counts in cases of secondary endodontic infections. The research focuses on the challenges of eliminating harmful microorganisms from the root canal system, which is crucial for the success of root canal treatments. By utilizing these advanced nano-based medications, the study aims to enhance the effectiveness of traditional endodontic procedures in treating infections that persist after initial treatments.
Who should consider this trial
Good fit: Ideal candidates include patients with single-rooted, single-canal premolar teeth that require non-surgical root canal retreatment due to signs of endodontic failure.
Not a fit: Patients with systemic diseases, pregnant or lactating individuals, and those with non-restorable teeth or significant periodontal issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the outcomes of root canal treatments by effectively eliminating persistent infections.
How similar studies have performed: While the use of nano-based medications is a relatively novel approach, similar studies have shown promising results in enhancing antimicrobial efficacy in dental treatments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Single rooted, single canal premolar teeth. * Teeth indicated for non-surgical root canal retreatment. * Teeth have signs and/or symptoms of post-treatment disease manifested by recurrent acute and/or chronic periapical abscess. * Teeth have clinical signs and symptoms of endodontic failure as sensitivity to percussion, pain, swelling or fistula. * Teeth with radiographic features of endodontic failure as persistent periapical lesion or widening of periodontal ligament. * Symptomatic or asymptomatic teeth with short root canal filling indicated for prosthetic restoration Exclusion Criteria: * Patients with any systemic diseases. * Pregnant or lactating patients. * Immunocompromised patients. * Non-restorable tooth. * Calcified root canal. * Teeth with root fracture. * Teeth with periodontal pocket deeper than 4mm. * Teeth have procedural error like ledge, broken instrument, or perforation
Where this trial is running
Tanta
- Faculty of Dentistry — Tanta, Egypt (Recruiting)
Study contacts
- Principal investigator: Abeer Darrag, Phd — Professor of Endodontics
- Study coordinator: Ibrahim Ali, bachelor
- Email: ibrahim3lii1995@gmail.com
- Phone: +201021294204
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.